Sepsis and Soft Tissue Infections

Clinical Care

Innovation Leader


Optimal outcomes and efficiencies for emergency department patients with sepsis and soft tissue infections through research, advocacy, education, and knowledge translation.

Current Activities

  • Initiation of RCT of C-reactive protein as screening tool for blood cultures in patients with sepsis
  • Retrospective identification of biochemical and demographic markers for high-risk sepsis patients
  • Development of best practices document for the treatment of skin and soft tissue infections
  • Partnering with BC Patient Safety & Quality Council for improvement in sepsis care across British Columbia

Short-Term Goals

  • Refine the criteria used to obtain blood cultures in emergency department patients with sepsis
  • Identify “low-risk sepsis patients” in whom blood cultures are not necessary, thus saving the health care system money
  • Investigate the role of biomarkers in patients with sepsis and use these in a risk stratification score
  • Strengthen partnerships with the BC Patient Safety & Quality Council the Canadian Association of Emergency Physicians (CAEP) Critical Care Committee in the development of a cohesive strategy of evidence-based care for patients with sepsis and septic shock through knowledge generation, knowledge translation, and evaluation
  • Build on existing relationships with the BC Ministry of Health Services/BC CDC and BC Centre for Excellence in HIV/AIDS to establish policy on point of care testing for HIV for all emergency department patients, and rapid linkage to care for patients found to be positive
  • Develop a strategy for routine testing for hepatitis C in the emergency department
  • Partner with industry and the BC Ministry of Health Services to develop a program of research on resistant bacteria (MRSA) and skin and soft tissue infections in the Emergency Department
  • Design research studies to identify high-risk patients with infections and sepsis in the Emergency Department
  • Continue to enroll patients in an open label, industry- sponsored trial of a reversal agent for patients with life threatening bleeding on dabigatran (a newer non-vitamin K antagonist anticoagulant)

Long-Term Goals

  • To ensure that patients with infections in emergency departments across BC receive timely and optimal evidence-based care
  • To establish our province as a leader in research and knowledge translation in this area